Examples of 'secukinumab' in a sentence
Meaning of "secukinumab"
Secukinumab (adjective): Referring to a type of monoclonal antibody medication used to treat conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by targeting specific proteins in the body's immune system to reduce inflammation
Show more definitions
- A human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, and psoriasis.
How to use "secukinumab" in a sentence
Basic
Advanced
secukinumab
The safety profile of secukinumab was favorable overall.
Cosentyx contains the active substance secukinumab.
It is not known whether secukinumab is excreted in human milk.
No secukinumab was administered in the placebo arm.
Placebo patients did not receive secukinumab injections.
The effect of secukinumab on human fertility has not been evaluated.
It contains the active substance secukinumab.
Antibodies to secukinumab were detected in only one of the exposed animals.
The results supported the subcutaneous administration of secukinumab.
Secukinumab has the potential to increase the risk of infections.
The safety profile of secukinumab is consistent across all indications.
The active substance is secukinumab.
Secukinumab clearance and volume of distribution increase as body weight increases.
Live vaccines should not be given concurrently with secukinumab.
Secukinumab is a monoclonal antibody.
See also
Body weight was identified as a covariate on secukinumab clearance and volumes.
Animal studies have not been conducted to evaluate the carcinogenic potential of secukinumab.
In patients treated with secukinumab compared to patients treated with ustekinumab.
Experimental PK values are compiled from various secukinumab psoriasis trials.
Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers.
In clinical studies, rare cases of anaphylactic reactions have been observed in patients receiving secukinumab.
There are no adequate data from the use of secukinumab in pregnant women.
However, secukinumab should not be given to patients with active tuberculosis.
The arrows indicate the time points of secukinumab administration.
Patients receiving secukinumab may receive concurrent inactivated or non-live vaccinations.
People who have had a severe allergic reaction to secukinumab should not use the medication.
Efficacy and safety of guselkumab were also investigated in a double-blind study compared to secukinumab.
This high binding affinity makes the secukinumab antibody particularly suitable for therapeutic applications.
A population approach with a two-compartmental model was used to describe secukinumab PK.
Interim data presented here suggests that secukinumab has use in treating active ankylosing spondylitis.
Secukinumab is a monoclonal antibody which belongs to a group of medicines called interleukin ( IL ) inhibitors.
The onset of action of secukinumab occurred as early as week 2.
What Cosentyx contains - The active substance is secukinumab.
Bioavailability of subcutaneously administered secukinumab was approximately 60 % compared to the intravenous administration.
Secukinumab is a recombinant fully human monoclonal antibody produced in Chinese Hamster Ovary ( CHO ) cells.
As a result, the time since last secukinumab administration differs within this group.
Secukinumab is a recombinant fully human monoclonal antibody selective for interleukin-17A.
Serious infections have been observed in patients receiving secukinumab in the post-marketing setting.
Is secukinumab easier to use?
Improvement in both endpoints was sustained for secukinumab patients who continued treatment through to week 24.
Each vial of powder for solution for injection contains 150 mg secukinumab.
The safety profile of secukinumab up to week 20 was comparable to placebo.
An additional Phase 3b study to compare bimekizumab directly with secukinumab has been initiated in June.
Five patients ( 4 secukinumab and 1 placebo ) were excluded from the efficacy analysis due to protocol violations.
No non-specific tissue cross-reactivity was observed when secukinumab was applied to normal human tissue.
Secukinumab is a humanized monoclonal antibody to IL-17 that is FDA-approved to treat psoriasis.
Anti-tuberculosis therapy should be considered prior to initiation of secukinumab in patients with latent tuberculosis.
Figure 10 shows simulated secukinumab pharmacokinetics ( PK ) in rheumatoid arthritis patients.
Table 4, Amino acid sequences of the hypervariable regions of the secukinumab monoclonal antibodies.
The single-use vial contains 150 mg secukinumab for reconstitution with sterile water for injections.
